AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02728349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorogenic acid
Description: Chlorogenic acid for injection is polyphenols, micromolecular and un-endogenous substance. It might play the role of cancer treatment via balancing tumor micro-environmental immune status according to the stability and rationality of immunodeficiency and endogenous immune material expression around the tumor. Chlorogenic acid for injection is made from chlorogenic acid (purity≥98%) which is extracted from folium cortex eucommiae.Chlorogenic acid and its preparations have not been reported as chemical drug and marketed around the world.
Study NCT03213327 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: StayOk web application
Description: Patients fill in the questionnaires of the web application and receive an analyzed profile of their psychosocial condition and health-promoting advices
Study NCT05619861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T
Description: Patients will receive CAR-T treatment
Study NCT02380209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CEST MRI
Description: CEST MRI will be performed on patients prior to surgical resection of their tumor
Study NCT03611205 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo dPET/CT
Study NCT03611205 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo dPET/CT
Study NCT00551980 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive, Relaxation, Exercise Therapy
Description: The intervention consists of brief shoulder and neck exercises to be performed several times a day, a relaxation exercise and instructions of how to reduce hyperfunction of the craniofacial and cervical muscles during the day
Study NCT05592925 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: coagulation-related factors
Description: We retrospectively evaluated the relationship between lymph node metastasis and coagulation-related factors in 516 patients with T4a stage gastric cancer.
Study NCT04112069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog
Description: iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog
Study NCT04112069 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care
Study NCT04540822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: peripheral venous catheter with compress under the catheter-extension tube junction
Description: Placement of a BD Insyte® type catheter of 20 to 24 Gauge calibre on a peripheral vein located in the crease of the elbow or top of the hand or scalp or top of the foot. The catheter is placed while respecting the detersion and disinfection of the skin with the appropriate products and according to the procedure in force in the department. Once the venous return has been checked, a 10 cm extension with a BECTON-DIC® 3-way valve will be connected, which is previously purged with 0.9% Sodium Chloride. Under the catheter-extension tube junction will be inserted a sterile non-woven compress, cut sterilely (3.5x1.5 cm). The assembly will be held in place by a transparent sterile semi-permeable adhesive dressing such as Tegaderm® (5x7 cm). This area will be secured by placing a crepe bandage (crepe bandage 4 m x7 cm).
Study NCT04540822 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: peripheral venous catheter without compress under the catheter-extension tube junction
Description: Placement of a BD Insyte® type catheter of 20 to 24 Gauge calibre on a peripheral vein located in the crease of the elbow or top of the hand or scalp or top of the foot. The catheter is placed while respecting the detersion and disinfection of the skin with the appropriate products and according to the procedure in force in the department. Once the venous return has been checked, a 10 cm extension with a BECTON-DIC® 3-way valve will be connected, which is previously purged with 0.9% Sodium Chloride. No compresses will be inserted under the catheter-extension tube junction.The assembly will be held in place by a transparent sterile semi-permeable adhesive dressing such as Tegaderm® (5x7 cm). This area will be secured by placing a crepe bandage (crepe bandage 4 m x7 cm).
Study NCT04682483 — intervention group
Intervention type: DRUG
Intervention: Vasopressor
Description: The vasopressors include phenylephrine, norepinephrine, epinephrine, dopamine and vasopressin.
Study NCT04682483 — intervention group
Intervention type: DRUG
Intervention: Inotrope
Description: Inotropes include dobutamine and milrinone.
Study NCT04682483 — intervention group
Intervention type: DEVICE
Intervention: Acute Mechanical Circulatory Support Devices
Description: Acute Mechanical Circulatory Support devices include ECMO (VV), ECMO (VA), Impella CP, Impella 2.5, Impella 5.0, Impella 5.5, Impella RP, IABP, Centrimag, Tandem Heart and ProTek Duo.
Study NCT02906735 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: Implantation of knee joint prosthesis or deviation osteotomies of the knee
Study NCT01565148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iCo-007 350 mcg
Description: iCo-007 (350 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (350 μg) at month 4
Study NCT01565148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iCo-007 700 mcg
Description: iCo-007 (700 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (700 μg) at month 4
Study NCT01565148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iCo-007 350 mcg and Laser
Description: iCo-007 (350 μg) as an intravitreal injection at baseline followed 7 days later by laser photocoagulation. At M4, intravitreal injection of iCo-007 (350 μg) will be given as mandatory treatment. If the eye also meets retreatment criteria, it will also receive the second laser photocoagulation
Study NCT01565148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab and iCo-007 350 mcg
Description: Ranibizumab (0.5 mg) intravitreal injection at baseline followed by iCo-007 (350 μg) intravitreal injection 2 weeks later; re-treatment with ranibizumab (0.5 mg) mandatory at M4 followed by iCo-007 (350 μg) 2 weeks later
Study NCT02414412 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ulmus macrocarpa water extract
Study NCT02414412 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ulmus macrocarpa water extract
Study NCT03560934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: Single dose oral administration of 10-60mg dronabinol prior to night 2 or 3 sleep in the clinical laboratory.
Study NCT02528188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID
Description: Orally administered NSAID (naproxen 500 mg, celecoxib 100 mg or diclofenac 75 mg) twice daily for 56 weeks
Study NCT02528188 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5 mg
Description: Subcutaneous injection of tanezumab 2.5 mg every 8 weeks for 56 weeks
Study NCT02528188 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab 5 mg
Description: Subcutaneous injection of tanezumab 5 mg every 8 weeks for 56 weeks
Study NCT02000349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PGD
Description: PGD using Next generation sequencing
Study NCT00505791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nesiritide
Description: Study drug will be administered for 24 hours. Study drug will be initiated with a 2-µg/kg loading bolus followed by .01-µg/kg/min infusion. This may be increased at a rate of .005-µg/kg/min. every 3 hours until maximum dose of .03-µg/kg/min. Any increase in the infusion rate will be preceded by a 1-µg/kg bolus and increases in infusion rates will be permitted only in patients who have a systolic blood pressure > 100 mmHg.
Study NCT00505791 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nesiritide
Description: Study drug will be administered for 24 hours. Study drug will be initiated with a 2-µg/kg loading bolus followed by .01-µg/kg/min infusion. This may be increased at a rate of .005-µg/kg/min. every 3 hours until maximum dose of .03-µg/kg/min. Any increase in the infusion rate will be preceded by a 1-µg/kg bolus and increases in infusion rates will be permitted only in patients who have a systolic blood pressure > 100 mmHg.
Study NCT02647268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin, 10-5M solution
Study NCT02647268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulphate
Description: Magnesium sulphate, 3.5mM solution
Study NCT00991107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HE3286
Description: HE3286 20 mg (10 mg BID) for 28 days
Study NCT00519389 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 VLP Vaccine
Description: Two doses - Day 0 \& Day 28
Study NCT00519389 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two doses - Day 0 \& Day 28
Study NCT02575560 — intervention group
Intervention type: OTHER
Intervention: history data
Description: history data of PFS after 1st line or second line theray
Study NCT00095667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given orally
Study NCT00095667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01579916 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Influenza Virus Vaccine
Description: Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10\^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H1N1 (A/California/7/2009), A/H3N2 (A/Victoria/361/2011), B (B Wisconsin/1/2010). A single dose of investigational product was administered on Day 1.
Study NCT01579916 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is suppllied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer. A single dose of investigational product was administered on Day 1.
Study NCT02399943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Study NCT02399943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Study NCT01591759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citicoline
Description: 2,000mg/day of citicoline taken as twice daily unit doses of 1,000 mg for the 8-week period of the clinical trial
Study NCT01591759 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo arm of single-blind study
Study NCT01376284 — intervention group
Intervention type: DRUG
Intervention: Dutasteride
Description: Collection of safety data
Study NCT04219657 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell application
Study NCT03643835 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal Rehab Machine
Description: The Polar Breeze unit is a microenvironmental air-chiller. That means it is a single-pass air-conditioner capable of cooling external air
Study NCT03643835 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Forearm Ice Towels
Description: Towels that are wetted with ice water and wrapped around participants forearms (length of arm from wrist to elbow)
Study NCT01321814 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy
Description: 6 sessions by licensed psychologist, including psychoeducation, exposure therapy, applied relaxation and behavioral activation.
Study NCT01847443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine (2 mg)
Description: 2 mg nicotine gum in two formulations
Study NCT01083017 — intervention group
Intervention type: DRUG
Intervention: standardized anti-hypertensive treatment
Description: olmesartan, amlodipine, chlorthalidone, +- spironolactone
Study NCT03362996 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Freshly-Pressed Extra Virgin Olive Oil
Description: Dietary Supplement: Freshly-pressed extra virgin olive oil Freshly-Pressed Extra Virgin Olive Oil Aluminum bottle with 500 ml of freshly-pressed extra virgin olive oil 1 bottle per 10 days
Study NCT03362996 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: extra virgin olive oil
Description: Extra Virgin Olive Oil Aluminum bottle with 500 ml of freshly-pressed extra virgin olive oil 1 bottle per 10 days
Study NCT03362996 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: mediterranean diet
Description: 50 patients that will have the same dietary habits and a Mediterranean dietary protocol
Study NCT01408563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2/day IV x 6 days
Study NCT01408563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 100 mg/m2/day IV x 1 day
Study NCT01408563 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Radiation
Description: 200 cGy on Day 0
Study NCT03573739 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low-calorie low-protein
Description: In the low-calorie low-protein (Low) group, the calorie target will be 6 kcal/kg/day and the protein target 0.2-0.4 g/kg/d during the acute phase, i.e. from D0 to D7. On D8, the calorie target will be 30 kcal/kg/d and the protein target 1.2-2.0 g/kg/d.
Study NCT03573739 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard-calorie/standard-protein
Description: In the standard-calorie/standard-protein (Standard) group, the first-line calorie target calculated based on body weight is 25 kcal/kg/day and the protein target 1.0-1.3 g/kg/d during the acute phase, i.e. from D0 to D7. On D8, the calorie target will be 30 kcal/kg/d and the protein target 1.2-2.0 g/kg/d.
Study NCT04259385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to sugar-sweetened beverage warning labels
Description: Graphic images of the amount of sugar (randomly assigned teaspoons, packets, or cubes) and text warning labels
Study NCT02082860 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: rAAV2/5-PBGD vector dosage 1
Description: Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
Study NCT02082860 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: rAAV2/5-PBGD vector dosage 2
Description: Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
Study NCT02082860 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: rAAV2/5-PBGD vector dosage 3
Description: Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
Study NCT02082860 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: rAAV2/5-PBGD vector dosage 4
Description: Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
Study NCT04473391 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cycle-ergometer training assisted by FES for lower extremities
Description: The intervention consists of FES treatment sessions on a cycle ergometer for the lower extremities. Each subject received 24 sessions lasting 45 minutes each and a frequency of 3 sessions per week. The sessions will be applied by a physiotherapist with experience in electrotherapy. A 6-channel FES device (TrainFES, Biomedical Devices SpA, Chile) will be used, which consists of a stimulator unit of 95x50x30mm and 100g of weight coupled to the motorized cycle ergometer (MOTOmed Viva 2, Reck GmbH., Germany), a remote user interface consisting of an android application for the configuration of the stimulation via Bluetooth 3.1, and an inertial measurement unit positioned on the rotation axis of the cycle ergometer to detect the rotations and trigger the synchronized electrical stimulation according to the stimulation pattern pre-configured for the pedaling exercise
Study NCT02370745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1
Description: GLP-1 effects on skeletal muscle glucose and amino acid metabolism and microvascular blood flow will be scrutinised under the specified insulin concentrations. It will also be used to test the effect of intravenous feed on insulin secretion.
Study NCT01408563 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cord Blood
Description: 2 cord blood units IV
Study NCT00560937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregnenolone
Description: Pregnenolone 50 mg twice a day (BID) x 2 weeks, Pregnenolone 150 mg BID x 2 weeks, Pregnenolone 250 mg BID x 4 weeks
Study NCT00560937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (similar to active comparator) 50 mg BID x 2 weeks, Placebo (similar to active comparator) 150 mg BID x 2 weeks, Placebo (similar to active comparator) 250 mg BID x 4 weeks
Study NCT02370745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Actrapid
Description: Skeletal muscle metabolic and microvascular parameters will be tested under specified insulin concentrations with or without GLP-1
Study NCT02370745 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral amino acids
Description: Oral amino acids containing 15 g of amino acids
Study NCT03442881 — intervention group
Intervention type: PROCEDURE
Intervention: Excision of adnexal mass through laprotomy
Description: Through laparotomy incision, the adnexal mass will be excised
Study NCT02804555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Oxygen administration
Study NCT00918463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: 100 mg daily dosing
Study NCT00963079 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embryo cryopreservation
Description: Cohort cryopreserved as bipronuclear (2pn) oocytes, then thawed and cultured to the blastocyst stage before transfer to the uterus.
Study NCT00963079 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fresh blastocyst transfer
Description: Fresh blastocyst transfer following cycle of controlled ovarian stimulation.
Study NCT04259385 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure to beverage calorie information
Description: Calories for sugar-sweetened and non-sugar-sweetened beverages
Study NCT04259385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to beverage calorie information
Description: Calories for sugar-sweetened and non-sugar-sweetened beverages
Study NCT01630096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nu-Lytely
Description: Bowl prep solution.
Study NCT02277704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TNX-102 SL
Study NCT02277704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02277704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT01847443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine (2 mg)
Description: 2 mg nicotine gum in two formulations
Study NCT01847443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine (4 mg)
Description: 4 mg nicotine gum in two formulations
Study NCT01847443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine (4 mg)
Description: 4 mg nicotine gum in two formulations
Study NCT03062943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Study NCT04052373 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantoplasty
Description: Implantoplasty is the mechanical smoothening of rough titanium implants as part of the surgical treatment of peri-implantitis. Treatment is thought to facilitate self-performed oral hygiene.
Study NCT04052373 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implantoplasty
Description: Implantoplasty is the mechanical smoothening of rough titanium implants as part of the surgical treatment of peri-implantitis. Treatment is thought to facilitate self-performed oral hygiene.
Study NCT04052373 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open flap debridement alone
Description: Open flap debridement alone
Study NCT04052373 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement alone
Description: Open flap debridement alone
Study NCT02321228 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Salpingectomy with delayed oophorectomy
Description: Early salpingectomy upon completions of childbearing with postponement of oophorectomy until between 40 and 45 in BRCA1 mutation carriers and between age 45 and 50 in BRCA2 mutation carriers.
Study NCT02321228 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Risk-reducing salpingo-oophorectomy
Description: This is the current guideline procedure, usually performed between age 35 and 40 in BRCA1 mutation carriers and between age 40 and 45 in BRCA2 mutation carriers.
Study NCT03596619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PBN
Description: The PBN-ALA-PDT group underwent vertical skin tapping with PBN before applying 10% ALA cream and narrow-band light-emitting diode (LED) irradiation (mean 633 nm, with a standard deviation \[SD\] of 10 nm; 100-200 J/cm2). The ALA-PDT group received ALA cream and irradiation only.
Study NCT02675153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Participants with gastrointestinal strictures were treated with rapamycin 2mg daily at least six months.